^
    Apply
    Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (AEWS1221) (NCT02306161)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/12/2014
    Primary completion :
    03/31/2021
    Completion :
    09/19/2025
    EGFR
    |
    doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • ganitumab (AMG 479)
    A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma (NCT04485949)
    Phase 2
    Imvax
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    03/20/2023
    Primary completion :
    01/01/2025
    Completion :
    07/01/2027
    MGMT
    |
    temozolomide • IGV-001
    Palbociclib + Ganitumab In Ewing Sarcoma (NCT04129151)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    02/14/2023
    Initiation :
    12/05/2019
    Primary completion :
    12/15/2022
    Completion :
    12/15/2022
    CDK4 • EWSR1 • IGF1 • FLI1 • FUS
    |
    Ibrance (palbociclib) • ganitumab (AMG 479)
    Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer (NCT01154335)
    Phase 1
    SCRI Development Innovations, LLC
    Completed
    Last update posted :
    05/03/2022
    Initiation :
    07/01/2010
    Primary completion :
    05/01/2013
    Completion :
    05/01/2013
    KRAS • ALK
    |
    KRAS mutation • KRAS wild-type • RAS wild-type
    |
    everolimus • linsitinib (ASP7487)
    S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00617708)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/08/2022
    Initiation :
    03/01/2008
    Primary completion :
    09/01/2012
    Completion :
    02/25/2014
    EGFR
    |
    erlotinib • gemcitabine • cixutumumab (IMC A12)
    Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer (NCT01446159)
    Phase 1b/2
    MedImmune LLC
    Completed
    Last update posted :
    06/02/2020
    Initiation :
    06/13/2011
    Primary completion :
    06/28/2019
    Completion :
    06/28/2019
    HER-2 • IGF2
    |
    exemestane • dusigitumab (MEDI-573)
    Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer (NCT00684983)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/24/2020
    Initiation :
    07/30/2008
    Primary completion :
    01/07/2014
    Completion :
    10/15/2019
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • lapatinib • capecitabine • cixutumumab (IMC A12)
    Preoperative Treatment With Cetuximab and/or IMC-A12 (NCT00957853)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    03/19/2020
    Initiation :
    10/17/2011
    Primary completion :
    08/15/2018
    Completion :
    08/15/2018
    EGFR
    |
    Erbitux (cetuximab) • cixutumumab (IMC A12)
    A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) (NCT00889382)
    Phase 1/2
    Astellas Pharma Inc
    Completed
    Last update posted :
    11/19/2019
    Initiation :
    08/05/2009
    Primary completion :
    08/01/2014
    Completion :
    08/25/2014
    MUC16
    |
    MUC16 elevation
    |
    paclitaxel • linsitinib (ASP7487)
    A Study in Non-Small Cell Lung Cancer (NCT01232452)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    09/20/2019
    Initiation :
    04/01/2011
    Primary completion :
    01/01/2013
    Completion :
    06/01/2016
    IGF1 • IGFBP3
    |
    cisplatin • pemetrexed • cixutumumab (IMC A12)
    A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer (NCT00781911)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    09/20/2019
    Initiation :
    02/01/2009
    Primary completion :
    07/01/2011
    Completion :
    05/01/2016
    IGF1 • IGF2
    |
    cixutumumab (IMC A12) • octreotide acetate solution for injection
    BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer (NCT01263782)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/15/2019
    Initiation :
    05/17/2011
    Primary completion :
    08/15/2017
    Completion :
    08/15/2017
    EGFR • ALK
    |
    EGFR mutation • ALK fusion
    |
    Avastin (bevacizumab) • carboplatin • pemetrexed • cixutumumab (IMC A12)
    A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors (NCT00816361)
    Phase 1
    MedImmune LLC
    Completed
    Last update posted :
    03/04/2019
    Initiation :
    03/09/2009
    Primary completion :
    09/11/2012
    Completion :
    09/11/2012
    IGF1 • IGF2
    |
    dusigitumab (MEDI-573)
    Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene (NCT01221077)
    Phase 2
    Astellas Pharma Inc
    Completed
    Last update posted :
    01/24/2019
    Initiation :
    04/08/2011
    Primary completion :
    03/01/2013
    Completion :
    09/01/2014
    EGFR
    |
    EGFR mutation • EGFR exon 19 deletion
    |
    erlotinib • linsitinib (ASP7487)
    Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (NCT01614795)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/11/2018
    Initiation :
    06/18/2012
    Primary completion :
    04/01/2014
    Completion :
    04/01/2014
    mTOR • IR
    |
    Torisel (temsirolimus) • cixutumumab (IMC A12)
    A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer (CARRIE) (NCT02399137)
    Phase 2
    Merrimack Pharmaceuticals
    Completed
    Last update posted :
    09/18/2018
    Initiation :
    05/01/2015
    Primary completion :
    08/01/2018
    Completion :
    08/01/2018
    IGF1
    |
    gemcitabine • albumin-bound paclitaxel • istiratumab (MM-141)
    Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy (NCT01186861)
    Phase 2
    Astellas Pharma Inc
    Completed
    Last update posted :
    09/05/2018
    Initiation :
    03/04/2011
    Primary completion :
    07/01/2013
    Completion :
    03/11/2015
    EGFR
    |
    EGFR mutation
    |
    erlotinib • linsitinib (ASP7487)
    A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) (NCT00759785)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    08/15/2018
    Initiation :
    09/30/2008
    Primary completion :
    02/17/2010
    Completion :
    02/17/2010
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR negative
    |
    dalotuzumab (MK 0646)
    Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) (NCT00614393)
    Phase 2
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    08/08/2018
    Initiation :
    12/24/2007
    Primary completion :
    06/01/2010
    Completion :
    03/07/2012
    KRAS
    |
    KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression
    |
    Erbitux (cetuximab) • irinotecan • dalotuzumab (MK 0646)
    Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy (NCT00503685)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    06/06/2018
    Initiation :
    06/01/2007
    Primary completion :
    03/01/2009
    Completion :
    03/01/2009
    KRAS • KIT • RAS • UGT1A1 • IGFBP2 • IGFBP3
    |
    KRAS mutation • RAS mutation • RAS wild-type • UGT1A1*1*1
    |
    Erbitux (cetuximab) • cixutumumab (IMC A12)
    A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer (NCT00728949)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    06/06/2018
    Initiation :
    08/01/2008
    Primary completion :
    03/01/2012
    Completion :
    02/01/2015
    ER • PGR
    |
    tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • cixutumumab (IMC A12)
    A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT01182883)
    Phase 1
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    07/02/2017
    Initiation :
    07/28/2010
    Primary completion :
    04/04/2012
    Completion :
    04/04/2012
    AFP
    |
    Torisel (temsirolimus) • cixutumumab (IMC A12)
    A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) (NCT01234857)
    Phase 2
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    05/31/2017
    Initiation :
    09/17/2010
    Primary completion :
    10/15/2013
    Completion :
    10/15/2013
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    exemestane • Taltorvic (ridaforolimus) • dalotuzumab (MK 0646)
    Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer (NCT02695550)
    Phase 1
    Centaurus Biopharma Co., Ltd.
    Unknown status
    Last update posted :
    03/09/2017
    Initiation :
    03/01/2016
    Primary completion :
    03/01/2018
    Completion :
    03/01/2018
    ALK
    |
    ALK positive • ALK rearrangement
    |
    Xalkori (crizotinib) • conteltinib (SY-707)
    QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma (NCT00813605)
    Phase 2
    NantCell, Inc.
    Completed
    Last update posted :
    10/27/2016
    Initiation :
    03/01/2009
    Primary completion :
    01/01/2011
    Completion :
    06/01/2012
    KRAS
    |
    KRAS mutation
    |
    5-fluorouracil • irinotecan • leucovorin calcium • ganitumab (AMG 479) • conatumumab (AMG 655)
    Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer (NCT01473303)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Withdrawn
    Last update posted :
    06/28/2016
    Initiation :
    08/01/2012
    Primary completion :
    08/01/2012
    UGT1A1
    |
    UGT1A1*28 • UGT1A1*1*1
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • ganitumab (AMG 479)
    Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008) (NCT00729742)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    04/04/2016
    Initiation :
    02/01/2009
    Primary completion :
    06/01/2010
    Completion :
    05/01/2011
    EGFR
    |
    EGFR mutation • EGFR amplification
    |
    erlotinib • dalotuzumab (MK 0646)
    Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer (NCT00719212)
    Phase 2
    Translational Research in Oncology
    Completed
    Last update posted :
    01/11/2016
    Initiation :
    01/01/2009
    Primary completion :
    05/01/2013
    Completion :
    05/01/2013
    MUC16
    |
    MUC16 elevation
    |
    ganitumab (AMG 479)
    Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer (NCT00678769)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    11/04/2015
    Initiation :
    05/01/2008
    Primary completion :
    06/01/2013
    Completion :
    10/01/2015
    PTEN • AKT1 • KDR • IRS1
    |
    Torisel (temsirolimus) • cixutumumab (IMC A12)
    Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer (NCT00678626)
    Phase 2
    Pfizer
    Withdrawn
    Last update posted :
    05/04/2015
    Initiation :
    04/01/2009
    Primary completion :
    09/01/2011
    Completion :
    09/01/2011
    HER-2
    |
    docetaxel • figitumumab (CP-751,871)